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Background. We performed a randomized phase II study comparing eﬃcacy and toxicity of weekly paclitaxel 80mg/m2 (Weetax)
with three weekly docetaxel 75mg/m2 (Threetax), both in combination with oral capecitabine 1000mg/m2 twice daily for 2 weeks
followed by a 1-week break. Patients. Thirty-seven women with conﬁrmed metastatic breast cancer were randomized. Results.
Median TTF was 174 (Weetax) versus 147 days (Threetax) (P = 0.472). Median OS was 933 (Weetax) versus 464 days (Threetax)
(P = 0.191). Reasons for TTF were PD 8/18 (Weetax), 9/19 (Threetax); and toxicity: 8/18 (Weetax), 8/19 (Threetax). ORR was
72% (Weetax) versus 26% (Threetax) (P = 0.01). The Threetax-combination resulted in a higher incidence of leuco-/neutropenia
compared to Weetax. Grade II anemia was more pronounced in the Weetax group. No diﬀerence was found in quality of life.
Conclusion. Taxanes in combination with capecitabine resulted in a high level of toxicity. Taxanes and capecitabine should be
considered given sequentially and not in combination.
1.Introduction
Docetaxel 100mg/m2 every 3 weeks has shown superiority
in comparison with Methotrexate/5-FU/Leukovorin (MFL)
[1] and mitomycin C/vinblastine (MV) [2] and has been
recognized and recommended as second line chemotherapy
in advanced metastatic breast cancer after failure on an
anthracycline containing regimen. Paclitaxel is an eﬀective
agent in the treatment of metastatic breast cancer. In phase
II and III trials where paclitaxel has been given every
third week at doses of 135–250mg/m2 administered by 3-
hour or 24-hour infusion, response rates of 23–60% have
been reported [3–7]. The activity and tolerability of weekly
dosing of paclitaxel have attracted much interest. Weekly
paclitaxel is usually associated with little myelosuppression
andmild-to-moderate reversibleneuropathy. Itis considered
as both dose-dense and dose-intense therapy and may,
therefore, have advantages with respect to cumulative drug
exposure. When given weekly by a 1-hour infusion in doses
of 80–100mg/m2, response rates of 21.5–68% have been
reported [8–11]. In 2002 O’Shaughnessy et al. published
the results of a phase III study comparing docetaxel alone
with docetaxel in combination with capecitabine [12]. A
superior TTP and overall survival achieved with the addi-
tion of capecitabine to docetaxel 75mg/m2 indicated that
this combination provides clear beneﬁts over single-agent
docetaxel100mg/m2.Thesideeﬀectsweredescribedasman-
ageable. Docetaxel/capecitabine therapy was described as an
important treatment option for women with anthracycline-
pretreated MBC [12]. In 2006 Blum et al. published the
results of a phase II study combining capecitabine with
weekly paclitaxel (80mg/m2) as 1st line treatment for
metastaticbreastcancer[13].Theobjectiveresponseratewas
55% and the regimen was described as active and tolerable
as ﬁrst-line therapy for women with MBC. We here describe
a randomized phase II study comparing docetaxel every
3 weeks with weekly paclitaxel, both in combination with
oralcapecitabine.Time-to-treatmentfailure(TTF),response
rates and quality of life were the main end points.
2.MaterialandMethods
Thirty-seven patients from 4 Norwegian hospitals were
randomized to weekly paclitaxel 80mg/m2 (Weetax) or2 Journal of Oncology
Table 1: Demographics and clinical characteristics of all randomised patients.
Docetaxel + capecitabine Paclitaxel + capecitabine
Median age (years) 52 (35–65) 53 (41–73)
Median weight (kg) 65 64.5
Median height (cm) 165 168.5
Median BSA (m2) 1.71 1.71
Performance status (ECOG)
08 1 2
I1 1 5
II 0 1
Estrogen receptor positive 12/19 12/18
Progesterone receptor positive 10/19 6/18
Prior postoperative radiotherapy 9/19 14/18
Prior radiotherapy for metastatic disease 7/19 2/18
Prior adjuvant chemotherapy 12/19 7/18
Prior chemotherapy for metastatic disease 12/19 11/18
Prior endocrine therapy for metastatic disease 14/19 12/18
Metastatic site
Liver 7/19 9/18
Lung 5/19 7/18
Bone 6/19 10/18
>2 metastatic sites 4/19 1/18
Diabetes 2/19 0/18
Thromboembolism 0/19 1/18
Cardiovascular disease 0/19 1/18
Time from diagnosis to ﬁrst recurrence (months) (CI) 55 (20–89) 33 (16–50)
docetaxel 75mg/m2 every three weeks (Threetax) both in
combination with oral capecitabine 1000mg/m2 twice daily
for 14 days followed by a 1-week break. Female patients
age 18 years or older with histologically conﬁrmed advanced
or metastatic HER2 negative breast cancer with measurable
or evaluable lesions were included. The chemotherapy was
given as 1st or 2nd line chemotherapy. In the Weetax group
11/18 patients had one chemotherapy regimen for metastatic
disease before inclusion compared to 12/19 patients in the
Threetax group. Prior adjuvant chemotherapy was permit-
ted. Concomitant bisphosphonate treatment was permitted.
G-CSF was not given. Loperamid was used for treatment-
related diarrhea.
Measurable disease was deﬁned as at least one lesion that
could be accurately measured in at least one dimension as
≥20mm by conventional techniques, or as ≥10mm by spiral
CTscan.Lyticbonemetastasesasonlysiteofrecurrencewere
allowed. ECOG performance status 0–2 and a life expectancy
of at least three months were required. The patients gave
written informed consent and had to be accessible for
treatment and follow-up. The patients were evaluated with
physical examination, CT-scan of target lesions, chest X-
ray, bone scan, X-ray of bones, and MRI. Other imaging
techniques were used as appropriate. An objective evaluation
of the treatment, limited to measurable/evaluable lesions,
was performed every 9 weeks until progression. Follow-
up after discontinuation of chemotherapy due to toxicity
or at patient’s request was carried out every 9 weeks until
progression: thereafter every 6 months or at the discretion
of the investigator. Objective response to treatment was
evaluated according to RECIST criteria for soft tissue and
visceral metastases [14] and according to WHO criteria
for bone metastases [15]. Main end points were time-to-
treatmentfailure(TTF)andQualityoflife.Qualityoflifewas
measuredatbaselineandafter2,4,6,and9months,utilizing
the EORTC QLQ-C30 (version 3) questionnaire [16].
Secondary end points were response rates, overall sur-
vival (OS), safety, and quality of life.
The study was registered in http://clinicaltrials.gov/ct2/
show/NCT00201435?term=nct00201435&amp;rank=1.
The Regional Ethics Committee, East Norway Health
Region, authorized the study (REK 378-04-03133). Patients
were informed that nonparticipation in the study would not
in any way jeopardize their medical treatment.
3.StatisticalMethods
To detect a diﬀerence of 20% in QOL between Weetax and
Threetax 36 patients needed to be randomized. Time-to-
treatment failure (TTF), response rate, overall survival, and
toxicity were analysed. TTF and overall survival analysis
included all patients and were calculated from the day of
study entry until the day of documented treatment failure or
death, respectively. Patients who died without documented
progression were censored on the day of death or last follow-
up. Patients who survived were censored on the day theyJournal of Oncology 3
Table 2: Treatment results.
Docetaxel + capecitabine (T) Paclitaxel + capecitabine (W)
Mean dose given (mg/m2) (% of planned dose)
Docetaxel 75.6 (94.6)
Paclitaxel 81.0 (101)
Capecitabine 1962.8 (98.1) 1990 (99.5)
Best response
CR 0/19 1/18
PR 4/19 12/18
SD 10/19 3/18
PD 4/19 1/18
Not evaluable for response 1/19 1/18
Main Reason for TTF
Disease progression 9/19 8/18
Toxicity 8/19 8/18
Patient’s request 2/19 2/18
TTF days 147 174
OS days 464 933
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Figure 1:Kaplan/Meieranalysisoftimetotreatmentfailure.Whole
line: Weetax. Dotted line: Threetax. Median time to treatment
failure: Weetax: 174 days. Threetax: 147 days (P = 0.472, n.s).
were last known to be alive. TTF and overall survival were
estimated using the Kaplan-Meier method.
4. Results
The patient characteristics are shown in Table 1.T h eg r o u p s
were well balanced. Median time from diagnosis to recur-
rence was 33 months (CI 16–50) in the Weetax group and 55
months (CI 20–89) in the Threetax group (not signiﬁcant).
The treatment results are summarized in Table 2.M e a n
dose given of planned dose was docetaxel 94.6%, paclitaxel
100%, capecitabine 99.5% (Weetax), and 98.5% (Threetax).
Overall response rate (CR + PR) was 13/18 (72%, W)
versus 5/19 (26%, T) (P = 0.01). Two patients, one in
each group, were not evaluable. Stable disease (SD) was
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Figure 2: Kaplan/Meier analysis of overall survival. Whole line:
Weetax. Dottedline:Threetax. Medianoverallsurvival:Weetax: 933
days. Threetax: 464 days (P = 0.191, n.s).
seen in 3 patients in the paclitaxel group and in 9 patients
in the docetaxel group. Progressive disease (PD) was seen
in 1/18 (Weetax) versus 4/19 (Threetax). The diﬀerence is
borderline signiﬁcant (P = 0.052). Median TTF was 174
(Weetax) versus 147 days (Threetax) (P = 0.472, n.s.)
(Figure 1). The main reasons for TTF were as follows; PD
8/18 (Weetax), 9/19 (Threetax); toxicity: 8/18 (Weetax),
8/19 (Threetax); and patient’s request: 2/18 (Weetax), 2/19
(Threetax). Median OS was 933 (Weetax) versus 464 days
(Threetax) (P = 0.191 n.s.) (Figure 2).
4.1. Toxicities. The Threetax-combination resulted in a sig-
niﬁcantly higher incidence of leucopenia and neutropenia
compared to Weetax (Table 3). There was no signiﬁcant
diﬀerence with respect to Palmar-Plantar Erythrodysesthesia4 Journal of Oncology
Table 3: Incidence of drug-related toxicities grades 2 to 4.
Toxicity
Docetaxel + capecitabine Paclitaxel + capecitabine
N = 19 N = 18
Grade I and II Grade III and IV Grade I and II Grade III and IV
Hematological
Leukopenia 3 (15.8%) 9 (47.4%) 10 (55.6%) 0 P = 0.001
Neutropenia 0 12 (63.2%) 9 (50.0%) 3 (16.7%) p = 0005
Febrile neutropenia NA 1 (5.3%) NA 1 (5,6%) n.s.
Anemia 3 (15.8%) 0 14 (77.8%) 0 0.002
Non-hematological
Infection NA 1 (5.3%) NA 2 (11.1%) n.s.
Mucositis 9 (47.4%) 0 5 (27.8%) 0 n.s.
Pain 5 (26.3%) 0 6 (33.3%) 1 (5.6%) n.s.
Fatigue 7 (36.8%) 1 (5.3%) 12 (67.7%) 1 (5.6%) n:s
Diarrhoea 7 (36.8%) 0 3 (16.7%) 0 n.s.
Neuropathy, sensory 3 (15.8%) 0 7 (38.9%) 0 n.s.
PPE∗ 8 (42.1%) 1 (5.3%) 9 (50%) 4 (22.2%) n.s.
Nail changes 7 (36.8%) 1 (5.3%) 11 (55.6%) 1 (5.6) n.s.
∗Palmar-Plantar Erythrodysesthesia.
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Figure 3: QLQ-C30 Global health status and functional scores.Journal of Oncology 5
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Figure 4: Figure 3. QLQ-C30 symptom scale scores and ﬁnancial problems.6 Journal of Oncology
(PPE) and nail changes grade 3 and 4. In the Weetax group,
however, there was more grade 2 toxicity with respect to PPE
and nail changes.
Grade II anemia was signiﬁcantly more pronounced in
the Weetax-group.
4.2.QualityofLife. TheresultsarepresentedinFigures3and
4. The physical,emotional, and cognitive functioning were at
a high level in both groups. The role and social functioning
were somewhat lower. There was no signiﬁcant diﬀerence
found between the groups. No statistical diﬀerence was
found between the two regimens with respect to global score
of QLQ-C30. Further, there were no diﬀerences with respect
to appetite loss, nausea, constipation, diarrhea, insomnia,
dyspnea, fatigue, and ﬁnancial problems. The level of pain
was lower in the Weetax-group compared to the Threetax
group at baseline and at all measured time points except one.
Insomnia had a higher—but not signiﬁcant—score in the
Threetax group.
5. Discussion
Time-to-treatment failure (TTF), rarely used as a primary
end point, considers any reason for treatment interruption
as an event in a Kaplan-Meier analysis (disease progression,
treatmenttoxicity,patientpreference,ordeath)whereastime
to progression (TTP) focuses on progression of disease.
Because TTF in its original deﬁnition is a composite end
point that also includes subjective symptom assessment, it
is seldom used for regulatory purposes. In spite of this TTF
is the end point perhaps best reﬂecting the clinical situation.
Our purpose was to perform a study that could be as close
to the real life clinical situation as possible. We found that
weeklypaclitaxelanddocetaxelevery3weeksincombination
with capecitabine resulted in stopping treatment due to
toxicity and patients’ preference in 10/18 in the paclitaxel
group and 10/19 in the docetaxel group, that is, in more
than 50% of the patients. This is a very high percentage
especially taking into consideration that this was a ﬁrst
or second line regimen for treatment of metastatic breast
cancer. The patients received more than 94% of the planned
doses indicating that dose reduction was seldom performed
due to hematological and nonhematological toxicity.
There was however signiﬁcant more leuco-/neutropenia
in the Threetax-group. This is as expected because weekly
paclitaxelisassociatedwithlittlebonemarrowtoxicity.Inthe
Threetax-group more patients received palliative radiother-
apy. This may have contributed to increased marrow toxicity.
The TTF for the two groups was 174 (Weetax) versus
147 days (Threetax), respectively. The TTF for Weetax is
comparable to the TTP reported by O’Shaugnessy for the
combination of docetaxel and capecitabine [12]( 5 ,8v e r s u s
6, 1 months).
In spite of this lack of diﬀerence between the groups with
respect to TTF, a signiﬁcant diﬀerence in response rates was
found. The response rate in the paclitaxel/capecitabine arm
corresponds well with what was found by Blum et al. [13].
They reported a response rate of 55% and a clinical beneﬁt
of 65%. The response rate in the docetaxel/capecitabine arm
was lower than that in the O’Shaugnessy study [12] (26%
versus 42%), but the number of patients with stable disease
was quite high in our study (9/19 patients). The median
overall survival is twice as high in the Weetax group as
compared with the Threetax group (933 versus 464 days),
but the diﬀerence does not reach statistical signiﬁcance. The
weakness of this study is the small number of patients. The
observed diﬀerences might therefore have been caused by
chance. The main message would be that the combination
of taxanes and capecitabine in the doses used in this study
is too toxic for routine use. This is in line with Susnjar
et al. who reported undue skin toxicity with a paclitaxel
dose exceeding 60mg/m2 when combined with capecitabine
1000mg/m2 twice daily [17], whereas others (Uhlmann et al.
[18] and Di Costanzo et al. [19]) recommended the doses
used in our trial. The recent meta-analysis by Gennari and
colleagues indicates that strategies for extending ﬁrst-line
chemotherapy are associated with a clinically modest but
statistically signiﬁcant improvement in OS and a clinically
meaningful and statistically signiﬁcant improvement in PFS
[20]. They point out that we may be able to accomplish
more by designing newer treatment sequences that use single
agents in sequential fashion. This viewpoint is supported
by Lidia Scapira commenting on this paper [21]. This is in
accordance with our own opinion.
6. Conclusion
Based on the experiences from this study, we recommend
that taxanes and capecitabine should be considered used in
sequence instead of in combination.
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